FIELD: biotechnology.
SUBSTANCE: disclosed are an antibody or an antigen-binding fragment thereof, binding to human IL-4R, a nucleic acid molecule encoding said antibody or the antigen-binding fragment thereof, a pharmaceutical composition for prevention or treatment of an IL-4R-mediated disease, containing an effective amount of said antibody and a pharmaceutically acceptable carrier, and a method for preventing or treating the disease, including administration of the antibody to a subject in need thereof.
EFFECT: inventions provide a possibility to produce new antibodies against human IL-4R, used in treatment of IL-4R-mediated diseases.
10 cl, 11 dwg, 12 tbl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| BISPECIFIC ANTIBODY AGAINST CD3E/BCMA AND ITS USE | 2019 |
|
RU2800164C2 |
| TETANUS TOXIN ANTIBODY AND USE THEREOF | 2020 |
|
RU2815280C1 |
| HUMAN TSLP ANTIBODIES AND USE THEREOF | 2021 |
|
RU2825460C1 |
| BISPECIFIC ANTIBODY AGAINST RABIES VIRUS AND ITS APPLICATION | 2019 |
|
RU2764740C1 |
| MONOCLONAL ANTIBODIES TO HUMAN IL-17 AND THEIR APPLICATION | 2016 |
|
RU2663721C1 |
| CORRESPONDING TARGET FOR TREATING FIBROSING DISEASES AND USE THEREOF | 2021 |
|
RU2830698C1 |
| ANTI-PDL-1 ANTIBODY, ITS PHARMACEUTICAL COMPOSITION AND USE | 2017 |
|
RU2693661C2 |
| ANTIBODY BINDING HUMAN IL-4R, ANTIGEN-BINDING FRAGMENT THEREOF, AND MEDICAL APPLICATION THEREOF | 2019 |
|
RU2779649C1 |
| ANTIBODY TO B7-H4, ITS ANTIGEN-BINDING FRAGMENT AND ITS PHARMACEUTICAL USE | 2019 |
|
RU2792748C2 |
| ANTI-CLDN-18.2 ANTIBODY AND USE THEREOF | 2021 |
|
RU2829997C1 |
